A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis
Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation
phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209
gel after transdermal administration in healthy male volunteers as a possible treatment
option for atopic dermatitis